Onychomycosis Clinical Trial
Official title:
Efficacy of Topical Resin Lacquer, Amorolfine, and Oral Terbinafine for Treating Toenail Onychomycosis: a Prospective, Randomized, Controlled, Investigator-blinded, Parallel-group Clinical Trial
The current study is conducted to corroborate the previous observational clinical trial with more valid methods and a more clinically relevant experimental design. This study aims to compare efficacy, safety, and cost between topically administered 30% resin lacquer for the treatment of dermatophyte toenail onychomycosis and the current "best practices": topical 5% amorolfine and systemic terbinafine.
The aim of this prospective, investigator-blinded, randomized and controlled clinical trial
is to explore potential differences between 5 % amorolfine and 30 % resin lacquer in topical
treatment of onychomycosis. In addition, topical treatment methods are compared with the
most effective 'drug of choice' for onychomycosis according the current guidelines i.e. oral
medication with terbinafine.
Altogether 90 patients (the aim is to collect the 30 patients per group) who have culture or
potassium hydroxide (KOH) stain verified dermatophyte onychomycosis are randomly allocated
into 3 treatment groups to receive either topical treatment or oral medication for toenail
onychomycosis classified as follows:
1. White superficial onychomycosis (WSO)
2. Distal and lateral subungual onychomycosis (DLSO)
3. Proximal subungual onychomycosis (PSO)
4. [Total dystrophic onychomycosis) (TDO)] [Excluded]
5. [Candidal onychomycosis] [Excluded]
Participants are randomized into 3 groups to receive:
1. Topical treatment: 30 % resin lacquer (Abicin®) applied once daily for 9 months.
2. Topical treatment: 5 % amorolfine lacquer (Loceryl®) applied once weekly for 9 months.
3. Oral medication: 250 mg terbinafine taken orally once daily for 3 months.
All patients visit at outpatient department before the launch of the study, and 3 and 9
months thereafter. Clinical examination is done by 4 physicians. During the 42-week study
period, laboratory tests are conducted on samples collected before treatment, at 20 weeks,
and at 42 weeks. The tests include a fungal culture, KOH staining of the toenail sample, and
blood tests. Cultures and KOH microscopy are performed in an independent, specialised
mycology laboratory with standard techniques (Medix Laboratories Ltd., Helsinki, Finland).
The blood tests measure plasma γ-glutamyl transferase levels (also at 2 weeks); plasma
creatinine levels; the total number of white blood cells, including neutrophils, monocytes,
basophils, lymphocytes, and eosinophils; the total number of red blood cells, including
erythrocytes and haematocrit; erythrocyte indices, including the mean corpuscular volume,
mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration, and haemoglobin
level; and the total number thrombocytes (initially and at 42 weeks). During the control
visits, sequential digital photographs of the most disfigured and brittle toenails are
acquired.
In the three phone calls, patients are asked about potential treatment-related side effects,
compliance with treatment, patients' perception of treatment outcome, and their willingness
to continue in the study. In each treatment arm, the treatment regimen is discontinued 5
weeks before the last toenail sampling to provide an appropriate washout period before the
final culture and KOH analysis.
To ensure safety and to assess potential contraindications for the treatment regimens, all
patients included in the study undergo a comprehensive medical interview and physical
examination. To identify patients who may develop intolerable adverse events due to drug
combinations, all concurrent medications are cross-checked to verify compatibility with
resin, amorolfine, and terbinafine regimens at the beginning of the study. All patients are
informed of the possibility of developing a hypersensitivity to resin, amorolfine, or
terbinafine. If patients experienced symptoms that corresponded to any level of
hypersensitivity, they are dropped from the study.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03098615 -
Study Evaluating the Effect of Jublia on Dermatophytomas
|
Phase 4 | |
Recruiting |
NCT01666002 -
Treatment of Onychomycosis Using a 0.65 Millisecond Pulsed Nd:YAG 1064 nm Laser
|
N/A | |
Terminated |
NCT01208129 -
Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails
|
Phase 3 | |
Terminated |
NCT01208168 -
Safety & Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails
|
Phase 3 | |
Completed |
NCT01180491 -
A Clinical Investigation on Early Visible Effects of Application of K101 During 8 Weeks on Discoloured and Deformed Nails Resulting From Onychomycosis
|
N/A | |
Completed |
NCT00385502 -
A Trial of the Safety and Efficacy of EcoNail™ in the Treatment of Fungus Infections of the Great Toenail
|
Phase 2 | |
Completed |
NCT00253305 -
Topical Gel Anti-Fungal Agent for Tinea Unguium
|
Phase 2 | |
Not yet recruiting |
NCT05809297 -
Diode Laser and Photodynamic Therapy Vs. Ciclopirox.
|
Phase 4 | |
Completed |
NCT03405818 -
An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents
|
Phase 4 | |
Completed |
NCT02588599 -
A Retrospective Analysis of the Effects of Low Level Laser Therapy on Toenail Onychomycosis
|
N/A | |
Recruiting |
NCT02436291 -
Evaluation of the Efficacy of CURE-EX Treatment in Onychomycosis
|
Phase 4 | |
Completed |
NCT01452490 -
Diode Laser Treatment of Onychomycosis
|
N/A | |
Withdrawn |
NCT00938925 -
Effectiveness of Podiatry Care on Onychomycosis (EPOCAON)
|
N/A | |
Recruiting |
NCT00808366 -
Efficacy and Safety of RV4104A Ointment in Onychomycosis
|
N/A | |
Completed |
NCT00781820 -
Comparative Efficacy of Bifonazole Cream vs Placebo After Nail Ablation With Urea Paste
|
Phase 3 | |
Completed |
NCT00768768 -
Iontophoretic Application of Terbinafine Gel to the Large Toe Nail
|
Phase 1 | |
Completed |
NCT00777868 -
A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-108 in Patients With Onychomycosis
|
Phase 2 | |
Recruiting |
NCT06074315 -
Evaluation of the Effectiveness of Nail Genesis DLSO Product for Onychomycosis
|
N/A | |
Completed |
NCT01039883 -
A Study to Compare the Blood Levels of Albaconazole in Healthy Subjects Who Have Received a Single Dose of 400 mg Albaconazole as a Tablet Versus Albaconazole as a Capsule
|
Phase 1 | |
Suspended |
NCT05491603 -
A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Onychomycosis
|
Phase 2 |